Seeking AlphaFri, 20 Mar 2026 07:25:29 GMTBoundless Bio: An Underestimated Biotech With A First-In-Class EcDNA Targeted Kinesin DegraderBOLD+4.49%
Zacks Investment ResearchFri, 13 Feb 2026 18:01:08 GMTBoundless Bio, Inc. (BOLD) Upgraded to Buy: Here's WhyBOLD+4.49%